A clinical trial update dated October 8, 2026 reports on the "French Registry of Children Treated With Norditropin® for Short Stature Associated With Noonan Syndrome," registered as NCT05308927. The study involves somatropin recombinant, marketed as Norditropin, and focuses on children with short stature associated with Noonan Syndrome.
According to the listing, the trial status is "enrolling by invitation." No phase is specified for this registry study. The update does not include any posted results or outcome data.
This registry is designed to follow children who are being treated with Norditropin for this specific indication. As an enrolling by invitation study, participation is limited to a predetermined group of candidates rather than open public enrollment.
No efficacy or safety findings are included in this update. The listing reflects only the current enrollment status and study design as of the stated date. Readers should not interpret this update as evidence of treatment outcomes, since none have been reported at this time.
Somatropin recombinant remains categorized under unapproved research status in the context referenced here. For additional background on this compound, readers can consult the compound overview.